Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Other Non Operating Income (2018 - 2024)

Historic Other Non Operating Income for Lipocine (LPCN) over the last 7 years, with Q4 2024 value amounting to $3586.0.

  • Lipocine's Other Non Operating Income fell 7078.38% to $3586.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $17165.0, marking a year-over-year decrease of 9192.96%. This contributed to the annual value of $17166.0 for FY2024, which is 9192.91% down from last year.
  • Lipocine's Other Non Operating Income amounted to $3586.0 in Q4 2024, which was down 7078.38% from $138081.0 recorded in Q3 2024.
  • Lipocine's Other Non Operating Income's 5-year high stood at $583445.0 during Q2 2022, with a 5-year trough of -$3.8 million in Q2 2021.
  • For the 5-year period, Lipocine's Other Non Operating Income averaged around -$292300.4, with its median value being $19864.5 (2023).
  • Within the past 5 years, the most significant YoY rise in Lipocine's Other Non Operating Income was 26622.14% (2020), while the steepest drop was 258409.51% (2020).
  • Lipocine's Other Non Operating Income (Quarter) stood at $290398.0 in 2020, then crashed by 155.07% to -$159926.0 in 2021, then skyrocketed by 121.41% to $34243.0 in 2022, then tumbled by 64.16% to $12274.0 in 2023, then tumbled by 70.78% to $3586.0 in 2024.
  • Its last three reported values are $3586.0 in Q4 2024, $138081.0 for Q3 2024, and -$84430.0 during Q2 2024.